Keen Vision Acquisition Corporation (KVAC)
| Market Cap | 121.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 7.41M |
| Shares Out | 10.82M |
| EPS (ttm) | 0.41 |
| PE Ratio | 27.18 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9 |
| Open | 11.24 |
| Previous Close | 11.24 |
| Day's Range | 11.22 - 11.24 |
| 52-Week Range | 10.47 - 11.24 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About KVAC
Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was formerly known as Central Acquisition Limited and changed its name to Keen Vision Acquisition Corporation in September 2021. Keen Vision Acquisition Corporatio... [Read more]
Financial Performance
Financial StatementsNews
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation ther...
Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction
BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmet need by developing a range of next-gene...
Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction
BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a r...
Medera's Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht
Cutting-Edge Cardiac Research: Novoheart's CTScreen™ system has been installed at UMC Utrecht, equipping Regenerative Medicine Center with advanced high-throughput tools to accelerate human cardiac di...
Medera, Inc. to Participate in Two Upcoming Investor Conferences
SUMMIT, N.J. and BOSTON, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Medera, Inc., (“Medera”), a clinical-stage biotechnology company, announced today that the management team will participate in the two upcomi...
Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology
Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs Human-specific diseases c...
Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction
Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all ...
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation
Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bi...
Keen Vision Acquisition Corporation Announces the Separate Trading of its Ordinary Shares and Warrants, Commencing September 15, 2023
SUMMIT, N.J., Sept. 14, 2023 /PRNewswire/ -- Keen Vision Acquisition Corporation ("KVAC") announced today that, commencing September 15, 2023, holders of the units sold in the Company's initial public...